secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2025-06-18T23:59:59+00:00
Accession:  0001213900-25-055407
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex achieves database lock for RePOSA Phase 2 trial of IHL-42X; top-line results expected July 2025
--------------------------------------------------------------------------------

- Database lock achieved June 16, 2025, on schedule; final statistical analysis begins.
- Top-line results from Phase 2 trial of IHL-42X for obstructive sleep apnoea expected July 2025.
- IHL-42X is a first-in-class oral therapy for OSA; no approved oral pharmacological treatment exists.
- Trial evaluates IHL-42X in moderate to severe OSA patients unable/unwilling to use CPAP.
- Over 900 million people affected by OSA worldwide; IHL-42X aims to address underserved patient population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025055407/0001213900-25-055407-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390025055407/ea0245975-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055407

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer